ArticleJournal of cancer survivorship : research and practice2026
Effect of an integrated mHealth supportive care program on symptom burden and self-efficacy in post-treatment breast cancer survivors: a randomized controlled trial.
Article in Journal of cancer survivorship : research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeThis randomized controlled trial evaluated the efficacy of a multidisciplinary, mobile health (mHealth) supportive care program designed to alleviate symptom burden and enhance self-efficacy in post-treatment breast cancer survivors (BCS). Secondary outcomes included quality of life (QoL), coping strategies, and inflammatory biomarkers.
methodsWe conducted a single-blind, randomized controlled trial involving 108 BCS. Participants were allocated to either a 3-month mHealth intervention (n = 54) delivered via the "ThrivePath" app or a routine care control group (n = 54). The app provided structured symptom monitoring, educational resources, and personalized support. Outcomes were assessed at baseline, 3 months (post-intervention), and 6 months (follow-up) and analyzed using linear mixed models.
resultsCompared to controls, the intervention group showed a significant reduction in symptom burden (β = -9.44, p < 0.001) and a significant increase in self-efficacy (β = 5.45, p < 0.001). The program also improved QoL, enhanced confrontation coping, and led to a significant reduction of pro-inflammatory cytokines (IL-1β, IL-2, IL-6, TNF-α) while preserving anti-inflammatory IL-10 levels.
conclusionsThe "ThrivePath" mHealth program is an effective, scalable intervention for post-treatment breast cancer survivors. It significantly reduces symptom burden and modulates inflammatory processes while boosting self-efficacy, offering an evidence-based model for delivering comprehensive survivorship care. IMPLICATIONS FOR CANCER SURVIVORS: The ThrivePath program provides a practical and accessible tool for survivors to manage their health following active treatment. By facilitating access to evidence-based resources and enabling direct communication with a care team, the program can help alleviate persistent symptoms, build confidence in self-management, and improve overall quality of life during the transition to survivorship.
trial registrationChiCTR2500108128.
Indexed as
Identifiers
41714554What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.